Lenalidomide Lymphoma MAGNIFY (CC-5013-NHL-008)
To improve your website experience, we use cookies and other tracking technologies and may share data with service providers.
By clicking 'Accept', you agree to the collection of data and use of these tracking technologies as described in our Privacy PolicyOpens new window. Select 'Decline' for essential cookies only.
Accept Decline Customize Your Preferences Opens new windowJump to content
- Set Your Location
- Sign in or Enroll
- Find a Doctor
- Find a Location
- Donate Now
- Patient Login
- Sign In to My Health Online
- Enroll in My Health Online
- Learn About My Health Online
- Enter a search term: View all resultsfor
Change Location
- Home
- Research
- Topic
Check-ups, screenings and sick visits for adults and children.
Specialty CareExpertise and advanced technologies in all areas of medicine.
Emergency CareFor serious accidents, injuries and conditions that require immediate medical care.
Urgent CareAfter-hours, weekend and holiday services.
Walk-In CareConvenient walk-in care clinics for your non-urgent health needs.
Từ khóa » Cc-5013-nhl-007
-
Rituximab Plus Lenalidomide For Patients With Relapsed ...
-
[PDF] CELGENE PROPRIETARY INFORMATION
-
EU Clinical Trials Register
-
A Phase III Study Of Lenalidomide Plus Rituximab Versus Placebo ...
-
Celgene-cc-5013-nhl-007 By Gibbs - Issuu
-
Clinical Trials - Mayo Foundation For Medical Education And Research
-
Revlimid 5 Mg Hard Capsules - Summary Of Product Characteristics ...
-
[PDF] Lenalidomide-accord-epar-product-information_en.pdf
-
Lenalidomide - Celgene Corporation - AdisInsight - Springer
-
ICTRP Search Portal
-
[PDF] Revlimid, INN-lenalidomide - European Medicines Agency
-
[PDF] EU-RISK MANAGEMENT PLAN FOR REVLIMID (LENALIDOMIDE)
-
Lymphoma & Myeloma Clinical Trials | MD Anderson Cancer Center
-
[PDF] SMC2281 - Scottish Medicines Consortium